Alto Neuroscience

Filed a patent for "method of treatment and selection of patients benefiting from agomelatine based on eeg measurements" on Thu, August 10, 2023

Filed a patent for "method of treatment and selection of patients benefiting from agomelatine based on eeg measurements" on Thu, February 13, 2025

Filed a patent for "method of treatment and selection of patients benefiting from agomelatine based on eeg measurements" on Thu, February 13, 2025

Filed a patent for "method of treatment and selection of patients benefiting from agomelatine based on eeg measurements" on Thu, February 13, 2025

Filed a patent for "method of treatment of depressed patients with poor cognition and selection of other patients benefiting from a benzylpiperazine-aminopyridine agent" on Thu, October 17, 2024

Filed a patent for "method of treatment of depressed patients with poor cognition and selection of other patients benefiting from a benzylpiperazine-aminopyridine agent" on Thu, October 17, 2024

Filed a patent for "effective treatment of depression in patients having impaired learning and/or memory or certain eeg characteristics with a benzylpiperazine-aminopyridine agent" on Thu, September 19, 2024

Filed a patent for "effective treatment of depression in patients having impaired learning and/or memory or certain eeg characteristics with a benzylpiperazine-aminopyridine agent" on Thu, September 26, 2024

Filed a patent for "effective treatment of depression in patients having impaired learning and/or memory or certain eeg characteristics with a benzylpiperazine-aminopyridine agent" on Thu, September 19, 2024

Filed a patent for "effective treatment of depression in patients having impaired learning and/or memory or certain eeg characteristics with a benzylpiperazine-aminopyridine agent" on Thu, September 19, 2024

Filed a patent for "method of treatment of depressed patients with poor cognition and selection of other patients benefiting from a benzylpiperazine-aminopyridine agent" on Thu, September 19, 2024

Filed a patent for "method of treatment of depressed patients with poor cognition and selection of other patients benefiting from a benzylpiperazine-aminopyridine agent" on Thu, September 19, 2024

Filed a patent for "effective treatment of depression in patients having impaired learning and/or memory or certain eeg characteristics with a benzylpiperazine-aminopyridine agent" on Mon, December 5, 2022

Filed a patent for "effective treatment of depression in patients having impaired learning and/or memory or certain eeg characteristics with a benzylpiperazine-aminopyridine agent" on Wed, August 30, 2023

Filed a patent for "effective treatment of depression in patients having impaired learning and/or memory or certain eeg characteristics with a benzylpiperazine-aminopyridine agent" on Thu, June 20, 2024

Filed a patent for "method of treatment of depressed patients with poor cognition and selection of other patients benefiting from a benzylpiperazine-aminopyridine agent" on Thu, December 8, 2022